Roche Completes Takeover of Genentech
BASEL, Switzerland -- Swiss pharmaceutical giant Roche said Thursday it has completed its $46.8 billion takeover of California biotech firm Genentech(DNA Quote).
Roche, which already held 55.7% of Genentech stock, said it acquired a further 37.5% of shares by the offer deadline on Wednesday. Roche said it has been guaranteed the transfer of a further 3% of Genentech shares in the coming days, taking its total holding to 96.2% and allowing the two companies to undergo a short-form merger. The deal ends Roche's long-running effort to take control of Genentech and secure the South San Francisco, Calif.-based biotech company's lucrative product portfolio, including the cancer drug Avastin. Genentech's board twice rejected Roche's advances until the Basel-based firm raised its offer to $95 a share. Roche expects to save $750 million to $850 million a year through the takeover, but has not said how many jobs could be lost.- Loading Comments...
- Loading Comments...
Recent Comments
Featured Photo Galleries
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,464.40 | 1,110.63 | 2,176.05 | 32.79 |
Oil *
77.06
|
|
UP
30.69
|
UP
4.98
|
UP
6.87
|
DOWN
0.38
|
10 Yr
3.28%
SPDR Gold
116.62
|
|
+0.29%
|
+0.45%
|
+0.32%
|
-1.15%
|
Data delayed 20 minutes |














